Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125303 | 0.91 | TRPV1 (0.76) | TRPV1HDAC6 | |
| SCHEMBL5131466 | 0.89 | TRPV1 (1.00) | TRPV1HDAC6 | |
| SCHEMBL5127961 | 0.88 | TRPV1 (0.71) | TRPV1HDAC6 | |
| SCHEMBL5802138 | 0.85 | TRPV1 (1.00) | TRPV1HDAC6 | |
| SCHEMBL5127495 | 0.83 | TRPV1 (0.61) | TRPV1 | |
| SCHEMBL5126063 | 0.80 | TRPV1 (0.60) | TRPV1 | |
| SCHEMBL5123770 | 0.80 | TRPV1 (0.70) | TRPV1 | |
| SCHEMBL5131743 | 0.80 | TRPV1 (0.83) | TRPV1HDAC6 | |
| SCHEMBL5122447 | 0.79 | TRPV1 (0.59) | TRPV1HDAC6 | |
| SCHEMBL5132186 | 0.79 | TRPV1 (0.59) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070946-A1 | Hydroxymethylbenzothiazoles Amides | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | US | claimed |
| CN-101035775-A | New hydroxymethylbenzothiazoles amides | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | CN | claimed |
| EP-1799661-A1 | NEW HYDROXYMETHYLBENZOTHIAZOLES AMIDES | AstraZeneca AB (SE) | 2007-06-27 | — | — | EP | claimed |
| WO-2006038871-A1 | NEW HYDROXYMETHYLBENZOTHIAZOLES AMIDES | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | WO | claimed |
| US-20080070946-A1 | Hydroxymethylbenzothiazoles Amides | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | US | disclosed |
| CN-101035775-A | New hydroxymethylbenzothiazoles amides | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | CN | disclosed |
| EP-1799661-A1 | NEW HYDROXYMETHYLBENZOTHIAZOLES AMIDES | AstraZeneca AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038871-A1 | NEW HYDROXYMETHYLBENZOTHIAZOLES AMIDES | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070946-A1 | Hydroxymethylbenzothiazoles Amides | TPMT, SDHA, SDHB | TRPV1 458/4885HDAC6 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.